Beyond Air (XAIR) announced the submission of a premarket approval, PMA, supplement application to the U.S. Food and Drug Administration, FDA, for LungFit PH II, the next-generation therapeutic nitric oxide generator. Beyond Air has developed its LungFit PH II system to be smaller, lighter and fully transport-ready – while delivering all the breakthrough features of the currently FDA-approved version from the Company’s therapeutic platform of nitric oxide generators targeting pulmonary disease. The new system uses the same Smart Filter and accessories as the first-generation device, ensuring continuity, streamlined logistics, and minimal disruption for existing customers.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR: